Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-208-20 D-0622-2017
Class III · Low risk

Ciclopirox Olamine Cream USP

Labeling: Incorrect or Missing Package Insert: product lots packaged with an out-of-date insert.

Terminated Labeling / mix-up G & W Laboratories, Inc. NDC 0713-0638-15 D-0636-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3953-09 D-0621-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3952-09 D-0620-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3951-09 D-0619-2017
Class II · Moderate risk

Atorvastatin Calcium Tablets

Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.

Terminated Microbial contamination Mylan Pharmaceuticals Inc. NDC 0378-3950-77 D-0618-2017
Class III · Low risk

Fluocinonide Cream UPS

Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.

Terminated Cross-contamination Taro Pharmaceuticals U.S.A., Inc. NDC 51672-1254-3 D-0790-2017
Class I · High risk

EpiPen Jr. 2-Pak

Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication

Ongoing Packaging defect Meridian Medical Technologies a Pfizer Company NDC 49502-500-02 D-0691-2017
Class I · High risk

EpiPen 2-Pak

Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication

Ongoing Packaging defect Meridian Medical Technologies a Pfizer Company NDC 49502-500-02 D-0690-2017
Class II · Moderate risk

Metronidazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-001-24 D-0616-2017
Class II · Moderate risk

Levofloxacin Injection in 5% Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-048-24 D-0615-2017
Class II · Moderate risk

Fluconazole Injection

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-003-06 D-0614-2017
Class II · Moderate risk

Ciprofloxacin in Dextrose

Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Terminated Sterility / contamination Claris Lifesciences Inc NDC 36000-009-24 D-0613-2017
Class II · Moderate risk

hydrALAZINE HYDROCHLORIDE INJECTION

Temperature Abuse: Certain pieces of these lots distributed by McKesson Medical Surgical Inc. were inadvertently stored refrigerated rather than the labeled room temperature recommendation.

Terminated Temperature excursion Mckesson Medical Surgical NDC 63323-614-01 D-0668-2017

Recalls by year